Interne link ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results februari 27, 2019 om 12:00 PM UTC
Interne link ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day januari 29, 2019 om 01:30 PM UTC
Interne link ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10 januari 07, 2019 om 12:00 PM UTC
Interne link ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2 januari 02, 2019 om 12:00 PM UTC